Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs | BMJ Medicine

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

PDF +
Supplementary
Material

Research

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Mitra-Majumdar M, Powers JH, Brown BL, et al

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs

BMJ Medicine 2022;1:e000227. doi: 10.1136/bmjmed-2022-000227